



## Novel Developments in Invasive Lobular Breast Cancer: Diagnosis, Prognosis and Therapy

Guest Editors:

**Dr. Lubna Khaldi**

Department of Pathology, Saint  
Savvas Anticancer Hospital of  
Athens, 11522 Athens, Greece

**Dr. Nektarios Koufopoulos**

Second Department of  
Pathology, "Attikon" University  
Hospital, Medical School,  
National and Kapodistrian  
University of Athens, Athens,  
Greece

Deadline for manuscript  
submissions:

**1 March 2025**

### Message from the Guest Editors

Dear Colleagues,

Invasive lobular carcinoma is the most common special subtype of invasive breast carcinoma. In addition to its specific morphology, it has different clinical, imaging, molecular, and treatment features compared to invasive breast carcinoma of no special type, as well as other special histologic subtypes.

Recent developments in this field include the recognition of novel subtypes.

We are pleased to invite you to contribute articles to this Special Issue, which aims to add to existing knowledge concerning the diagnosis, prognosis, and treatment of invasive lobular breast cancer. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: clinical, imaging, pathologic, molecular, and treatment features of invasive lobular carcinoma.

We look forward to receiving your contributions.





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI